Previous 10 | Next 10 |
Shares of Invitae (NYSE: NVTA) were tumbling 10.9% as of 3:11 p.m. EDT on Wednesday. There weren't any new developments that explained the decline. Instead, the stock appeared to be dragged down in a broader sell-off of growth stocks. It's best to ignore short-term volatility, e...
Genetic testing is a hot market right now. But some of the companies involved in genetic testing have very different business models. In this Motley Fool Live video recorded on March 3, 2021 , Fool.com contributors Keith Speights and Brian Orelli address a viewer's question abo...
Invitae (NVTA) stock gaining as CNBC is set to appear on CNBC.Developing story ... For further details see: Invitae stock popping as CEO set to appear on CNBC
Shares of Invitae (NYSE: NVTA) were jumping 11.3% as of 3:05 p.m. EST on Thursday. The medical genetics company announced the issuance of its first environmental, social, and governance (ESG) report earlier in the day. However, the primary catalyst for Invitae was investors' renewed...
Invitae Releases Inaugural Environmental, Social and Governance (ESG) Report -- Benchmark report marks beginning of increased focus on sustainability issues, in recognition of their impact on its business and patient health -- PR Newswire SAN FRANCISCO , Ma...
AnPac Bio-Medical Science (ANPC) +75% after update on cancer detection system CDAPS.Second Sight Medical Products (EYES) +67%.GT Biopharma (GTBP) +45%.Auris Medical Holding Ltd. (EARS) +24%.Taoping Inc. (TAOP) +10% on launching Blockchain Business Division.AirNet Technology (ANTE) +...
The end may at last be coming for the pandemic (in the U.S.) at least, and with that, the era of the COVID hyper winner. We break down Zoom's earnings report and the market reaction and wonder whether that's a bellwether. We also look at some old school and new school economy gian...
Invitae (NVTA) gained 4% after ARK's Cathie Wood promoted the shares in a CNBC interview.Developing story ... For further details see: Invitae spikes to session highs on Cathie Wood positive comments
Invitae (NYSE: NVTA) is growing revenue quickly thanks to its acquisition of ArcherDx, which offers tests to determine the best drugs to treat tumors. But the diagnostic testing company is still losing a lot of money. In this video from Motley Fool Live , recorded on Feb. ...
Shares of Invitae (NYSE: NVTA) were down 8.6% as of 3:30 p.m. EST on Thursday. This marked the second consecutive session where the stock declined. Invitae hasn't announced any news that would cause its shares to slump. Instead, the stock continued to sink because of a broader marke...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...